SCHEMBL290573

SCHEMBL290573

CCOC(=O)C(O)C1(c2ccccc2)CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 6/20 0.46
OPRD1 P41143 4/20 0.45
OPRK1 P41145 4/20 0.45
SLC6A4 P31645 2/20 0.45
SLC22A1 O15245 1/20 0.45
ADRA1A P35348 1/20 0.45
KCNH2 Q12809 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PRCP P42785 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
PIN1 Q13526 1/20 0.42
HDAC4 P56524 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1612406 0.85 HDAC4 (0.47) OPRM1OPRK1SLC6A4MEN1KMT2A
SCHEMBL27296884 0.83 HDAC4 (0.46) OPRM1OPRK1SLC6A4MEN1KMT2A
SCHEMBL5690461 0.81 HDAC4 (0.37) OPRM1SLC6A4SLC22A1SMN1; SMN2MEN1
SCHEMBL28279427 0.80 OPRM1 (0.41) OPRM1OPRD1OPRK1SLC6A4SLC22A1
SCHEMBL5690328 0.79 HDAC4 (0.36) SMN1; SMN2MEN1KMT2ACYP1A2CYP3A4
SCHEMBL1904196 0.79 CHRM2 (0.50) OPRM1SLC22A1ADRA1AKCNH2SMN1; SMN2
SCHEMBL290754 0.79 HDAC4 (0.50) SLC6A4SMN1; SMN2MEN1KMT2AHDAC4
SCHEMBL27774530 0.79 HDAC4 (0.50) SLC6A4SMN1; SMN2MEN1KMT2AHDAC4
SCHEMBL19357459 0.79 SMN1; SMN2 (0.45) OPRM1OPRD1OPRK1SLC6A4SLC22A1
SCHEMBL1953126 0.77 AKR1C1 (0.50) SLC6A4SMN1; SMN2MEN1KMT2AHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10449173-B2 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions ALLERGAN SALES, LLC (US) 2019-10-22 US claimed
EP-3287122-B1 DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS FOR TREATING OVERACTIVE BLADDERS. ALLERGAN SALES LLC (US) 2019-04-17 EP claimed
EP-3287122-A1 A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS Allergan Sales, LLC (US) 2018-02-28 EP claimed
EP-2427172-B1 A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS ALLERGAN SALES LLC (US) 2017-11-01 EP claimed
US-20160128963-A1 METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS WATSON LABORATORIES, INC. 2016-05-12 US claimed
US-9259388-B2 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions WATSON PHARMACEUTICALS, INC. (US) 2016-02-16 US claimed
US-8920392-B2 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions WATSON LABORATORIES, INC. (US) 2014-12-30 US claimed
US-20140046275-A1 Method for Treating Overactive Bladders and a Device for Storage and Administration of Topical Oxybutynin Compositions WATSON LABORATORIES, INC. (US) 2014-02-13 US claimed
EP-2427172-A2 A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS Watson Laboratories, Inc. (US) 2012-03-14 EP claimed
WO-2010129498-A2 A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS WATSON LABORATORIES, INC. (US) 2010-11-11 WO claimed
US-20100286630-A1 Method For Treating Overactive Bladders And A Device For Storage And Administration Of Topical Oxybutynin Compositions WATSON LABORATORIES, INC. (US) 2010-11-11 US claimed
US-10449173-B2 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions ALLERGAN SALES, LLC (US) 2019-10-22 US disclosed
EP-3287122-B1 DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS FOR TREATING OVERACTIVE BLADDERS. ALLERGAN SALES LLC (US) 2019-04-17 EP disclosed
EP-3287122-A1 A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS Allergan Sales, LLC (US) 2018-02-28 EP disclosed
EP-2427172-B1 A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS ALLERGAN SALES LLC (US) 2017-11-01 EP disclosed
US-20140046275-A1 Method for Treating Overactive Bladders and a Device for Storage and Administration of Topical Oxybutynin Compositions WATSON LABORATORIES, INC. (US) 2014-02-13 US disclosed
EP-2427172-A2 A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS Watson Laboratories, Inc. (US) 2012-03-14 EP disclosed
WO-2010129498-A2 A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS WATSON LABORATORIES, INC. (US) 2010-11-11 WO disclosed
US-20100286630-A1 Method For Treating Overactive Bladders And A Device For Storage And Administration Of Topical Oxybutynin Compositions WATSON LABORATORIES, INC. (US) 2010-11-11 US disclosed
CN-1558756-A Pharmaceutical compositions for the treatment of urinary disorders �ź㴫 2004-12-29 CN disclosed